SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-18-000171
Filing Date
2018-02-21
Accepted
2018-02-21 16:32:44
Documents
2
Group Members
ORBIMED CAPITAL GP III LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 ss80874_sc13da.htm SC 13D/A 116445
2 JOINT FILING AGREEMENT ss80874_ex9901.htm EX-99.1 25169
  Complete submission text file 0000947871-18-000171.txt   143258
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 255 STATE STREET 9TH FLOOR BOSTON MA 02109
Business Address 255 STATE STREET 9TH FLOOR BOSTON MA 02109 857-246-8998
PIERIS PHARMACEUTICALS, INC. (Subject) CIK: 0001583648 (see all company filings)

IRS No.: 300784346 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88917 | Film No.: 18628887
SIC: 8731 Services-Commercial Physical & Biological Research
Office of Trade & Services